QT is not a problem. They asked the question during the CC. Those QTs were patients who did not have normal QT to start with. No QT prolongation was observed in other doses. They also mentioned that 543's ability to inhibit hERG is between Tasigna and Gleevec. Its really disappointing that market did not react favorably to the data.
News 
Market Data 
Discover 
AI
